Comparison of Bisulfite Pyrosequencing and Methylation-Specific qPCR for Methylation Assessment

Different methodological approaches are available to assess DNA methylation biomarkers. In this study, we evaluated two sodium bisulfite conversion-dependent methods, namely pyrosequencing and methylation-specific qPCR (MS-qPCR), with the aim of measuring the closeness of agreement of methylation values between these two methods and its effect when setting a cut-off. Methylation of tumor suppressor gene p16/INK4A was evaluated in 80 lung cancer patients from which cytological lymph node samples were obtained. Cluster analyses were used to establish methylated and unmethylated groups for each method. Agreement and concordance between pyrosequencing and MS-qPCR was evaluated with Pearson’s correlation, Bland–Altman, Cohen’s kappa index and ROC curve analyses. Based on these analyses, cut-offs were derived for MS-qPCR. An acceptable correlation (Pearson’s R2 = 0.738) was found between pyrosequencing (PYRmean) and MS-qPCR (NMP; normalized methylation percentage), providing similar clinical results when categorizing data as binary using cluster analysis. Compared to pyrosequencing, MS-qPCR tended to underestimate methylation for values between 0 and 15%, while for methylation >30% overestimation was observed. The estimated cut-off for MS-qPCR data based on cluster analysis, kappa-index agreement and ROC curve analysis were much lower than that derived from pyrosequencing. In conclusion, our results indicate that independently of the approach used for estimating the cut-off, the methylation percentage obtained through MS-qPCR is lower than that calculated for pyrosequencing. These differences in data and therefore in the cut-off should be examined when using methylation biomarkers in the clinical practice.

[1]  C. Šálek,et al.  DNA Methylation Validation Methods: a Coherent Review with Practical Comparison , 2019, Biological Procedures Online.

[2]  B. Singer,et al.  A Practical Guide to the Measurement and Analysis of DNA Methylation. , 2019, American journal of respiratory cell and molecular biology.

[3]  A. Fernández-Villar,et al.  Methylation Assessment for the Prediction of Malignancy in Mediastinal Adenopathies Obtained by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in Patients with Lung Cancer , 2019, Cancers.

[4]  Y. Assenov,et al.  Intratumor heterogeneity in epigenetic patterns. , 2018, Seminars in cancer biology.

[5]  Zhang Huayu,et al.  P16 INK4a gene promoter methylation as a biomarker for the diagnosis of non‐small cell lung cancer: An updated meta‐analysis , 2018, Thoracic cancer.

[6]  L. Stuyver,et al.  Droplet digital PCR is an accurate method to assess methylation status on FFPE samples , 2018, Epigenetics.

[7]  Guohong Liu,et al.  DNA methylation profiles in cancer diagnosis and therapeutics , 2018, Clinical and Experimental Medicine.

[8]  M. Esteller,et al.  Lung cancer epigenetics: From knowledge to applications. , 2017, Seminars in cancer biology.

[9]  J. Herman,et al.  Early Detection of Lung Cancer Using DNA Promoter Hypermethylation in Plasma and Sputum , 2016, Clinical Cancer Research.

[10]  K. Liestøl,et al.  Experimental factors affecting the robustness of DNA methylation analysis , 2016, Scientific Reports.

[11]  Kimberly Walter,et al.  Quantitative comparison of DNA methylation assays for biomarker development and clinical applications , 2016, Nature Biotechnology.

[12]  M. Bullock,et al.  DNA Methylation Analysis: Choosing the Right Method , 2016, Biology.

[13]  V. Kristensen,et al.  Heterogeneous DNA Methylation Patterns in the GSTP1 Promoter Lead to Discordant Results between Assay Technologies and Impede Its Implementation as Epigenetic Biomarkers in Breast Cancer , 2015, Genes.

[14]  G. Barreto,et al.  Epigenetics in lung cancer diagnosis and therapy , 2015, Cancer and Metastasis Reviews.

[15]  Martin S. Taylor,et al.  Quantification of epigenetic biomarkers: an evaluation of established and emerging methods for DNA methylation analysis , 2014, BMC Genomics.

[16]  T. Liloglou,et al.  Epigenetic biomarkers in lung cancer. , 2014, Cancer letters.

[17]  L. Tanoue,et al.  Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. , 2013, Chest.

[18]  F. Coppedè,et al.  Comparison Study of MS-HRM and Pyrosequencing Techniques for Quantification of APC and CDKN2A Gene Methylation , 2013, PloS one.

[19]  M. Sanson,et al.  Comparative assessment of 5 methods (methylation‐specific polymerase chain reaction, methylight, pyrosequencing, methylation‐sensitive high‐resolution melting, and immunohistochemistry) to analyze O6‐methylguanine‐DNA‐methyltranferase in a series of 100 glioblastoma patients , 2012, Cancer.

[20]  C. Plass,et al.  A systematic comparison of quantitative high-resolution DNA methylation analysis and methylation-specific PCR , 2012, Epigenetics.

[21]  Nicola Torelli,et al.  Clustering via nonparametric density estimation , 2007, Stat. Comput..

[22]  D. Mccrory,et al.  Endoscopic ultrasound-guided fine-needle aspiration for non-small cell lung cancer staging: A systematic review and metaanalysis. , 2007, Chest.

[23]  N. Cross,et al.  Quantitative Analysis of SRNPN Gene Methylation by Pyrosequencing as a Diagnostic Test for Prader–Willi Syndrome and Angelman Syndrome , 2006 .

[24]  Shuji Ogino,et al.  Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. , 2006, The Journal of molecular diagnostics : JMD.

[25]  S. Goodman,et al.  Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  J. Herman,et al.  Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas. , 2003, Carcinogenesis.

[27]  P. Laird,et al.  MethyLight: a high-throughput assay to measure DNA methylation. , 2000, Nucleic acids research.

[28]  D. Sidransky,et al.  Role of the p16 tumor suppressor gene in cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. Herman,et al.  5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.

[31]  Qihong Huang,et al.  Clinical Significance of P16 Gene Methylation in Lung Cancer. , 2020, Advances in Experimental Medicine and Biology.

[32]  I. Gut,et al.  Analysis of gene-specific DNA methylation patterns by pyrosequencing technology. , 2007, Methods in molecular biology.

[33]  N. Cross,et al.  Quantitative analysis of SNRPN(correction of SRNPN) gene methylation by pyrosequencing as a diagnostic test for Prader-Willi syndrome and Angelman syndrome. , 2006, Clinical chemistry.